What Happened
- A recent analysis highlights the growing recognition that commercial forces — particularly the pharmaceutical industry and the food industry — are major determinants of population health outcomes, alongside traditional social determinants like income, education, and housing.
- The framework of "Commercial Determinants of Health" (CDoH) — formally recognised by the WHO — argues that corporate decisions on production, pricing, marketing, and lobbying systematically shape what people eat, what medicines they can access, and how health policy is designed.
- In India's context, this framework intersects with two urgent policy debates: access to affordable medicines (where pharmaceutical patent policies and pricing controls are contested terrain), and the rapid rise of ultra-processed food consumption (where regulatory gaps and industry lobbying impede meaningful restrictions).
- The WHO has initiated a programme specifically targeting Commercial Determinants of Health, calling on member states to use fiscal measures (taxation), regulatory tools (labelling, advertising restrictions), and governance reforms (conflict-of-interest management) to counteract commercial health harms.
- India is at a critical inflection point: it is simultaneously the world's largest generic medicine supplier (a positive commercial health force globally) and facing a surging NCD burden linked to dietary patterns heavily influenced by processed food industry marketing.
Static Topic Bridges
Commercial Determinants of Health: The WHO Framework
The WHO defines Commercial Determinants of Health (CDoH) as "the conditions, actions, and omissions by commercial actors that affect health, arising in the context of the provision of goods or services for payment." This concept broadens the traditional social determinants framework (which focuses on poverty, education, housing, and social inequalities) to explicitly incorporate how corporate behaviour shapes health. The industries most documented as commercial health determinants include: tobacco, alcohol, ultra-processed food and beverages, pharmaceuticals, fossil fuels, and gambling. These industries employ common strategies — aggressive marketing, lobbying against regulation, scientific controversy manufacturing (the "playbook" first documented for tobacco) — to protect their commercial interests at the expense of public health.
- The WHO Framework Convention on Tobacco Control (FCTC), adopted in 2003 and ratified by 182 countries including India, is the first WHO treaty explicitly designed to counter a commercial determinant of health (tobacco industry).
- Approximately 50 countries including India have implemented sugar-sweetened beverage taxes as a fiscal tool against a commercial health determinant.
- The WHO's 2023 report estimated that commercial determinants contribute to over 19 million deaths annually from non-communicable diseases.
- India's NCD burden accounts for approximately 63% of all deaths — cardiovascular diseases, diabetes, cancer, and chronic respiratory diseases — with commercial determinants increasingly implicated.
- The term "industrial disease model" refers to the pattern where industries create products that cause harm, then profit from treating that harm — most vividly seen in tobacco, but relevant across sectors.
Connection to this news: The analysis positions India's health policy challenge not merely as a matter of public investment in healthcare, but as a governance challenge: how to regulate commercial interests that are embedded in both the food and medicine supply chains, and that actively resist measures that might curtail their markets.
India's Pharmaceutical Industry: The Access and Affordability Tension
India occupies a paradoxical position in global pharmaceutical commercial determinants: it is simultaneously the world's largest supplier of generic medicines (producing 20% of global supply by volume and supplying 60% of the world's vaccines) and a country where a substantial share of its own population lacks affordable access to essential medicines. The 1970 Patents Act, which excluded pharmaceutical product patents, allowed Indian companies to produce affordable generics of essential medicines — including HIV antiretrovirals that transformed treatment access in low-income countries. India's adoption of TRIPS (Trade-Related Aspects of Intellectual Property Rights) compliance in 2005 introduced product patents, creating tension between innovation protection and generic access.
- Section 3(d) of the Indian Patents Act prevents "evergreening" — blocking pharmaceutical companies from obtaining new patents merely for minor modifications of existing molecules without significant therapeutic improvement.
- India's National Pharmaceutical Pricing Authority (NPPA) regulates prices of essential medicines listed under the National List of Essential Medicines (NLEM); currently 348 drugs are price-controlled.
- Compulsory licensing (Section 84 of Patents Act): India can grant compulsory licences to allow generic production of patented drugs when the patent holder does not meet "reasonable requirements of the public" — Natco Pharma vs. Bayer (2012) is the landmark case.
- India's Jan Aushadhi scheme (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) — over 10,000 stores providing generic medicines at 50–90% below branded prices.
- Pharmaceutical companies spend approximately 20–30% of revenues on marketing — often more than on R&D — directing prescriber behaviour through samples, continuing medical education sponsorship, and other incentives.
Connection to this news: The pharmaceutical industry's pricing strategies, patent practices, and marketing to prescribers are classic examples of commercial determinants shaping health outcomes — and India's unique policy toolkit (Section 3(d), NPPA controls, compulsory licensing) represents some of the most robust global pushback against pharmaceutical commercial determinants.
Ultra-Processed Foods, India's NCD Burden, and Regulatory Gaps
India's food system is undergoing a rapid transition driven by commercial forces: the ultra-processed food and beverage (UPF) sector grew at a compound annual growth rate of 13.37% between 2011 and 2021, driven by aggressive marketing, urbanisation, and rising incomes. Ultra-processed foods — characterised by high fat, sugar, salt, and artificial additives, and classified under the NOVA system — are associated with obesity, type 2 diabetes, cardiovascular disease, and certain cancers. The ICMR-NIN estimates that 56.4% of India's total disease burden is linked to unhealthy diets. Yet India's regulatory response remains fragmented: the Food Safety and Standards Authority of India (FSSAI) has no formal definition for ultra-processed foods, and front-of-pack nutrition labelling (FOPNL) — mandated by the Supreme Court — remains under implementation.
- NOVA classification system (developed by researchers at the University of São Paulo) categorises food by degree of processing; Group 4 (ultra-processed) includes packaged snacks, instant noodles, carbonated drinks, and ready-to-eat meals.
- India's FSSAI (established under FSSAI Act, 2006) regulates food safety and standards; it is required to adopt ICMR-NIN norms for defining High Fat, Sugar, Salt (HFSS) foods for FOPNL.
- Economic Survey recommendation: strict front-of-pack warning labels, higher taxation, and advertising bans on ultra-processed foods.
- Modelling study finding: A 40% GST on HFSS items could reduce annual average disease incidence by up to 1.72% and prevent approximately 18.98 million DALYs over 30 years, with up to US$18 billion in avoided health expenditure.
- India currently taxes carbonated drinks at 28% GST plus 12% cess — but no specific "sugar tax" framework targeting all HFSS foods exists.
Connection to this news: India's FSSAI regulatory gaps and industry lobbying against strong FOPNL and taxation are a textbook commercial determinants dynamic — the food industry actively shapes regulatory outcomes in ways that protect market share at the expense of population health, consistent with the broader CDoH framework.
Key Facts & Data
- WHO definition of Commercial Determinants of Health: "conditions, actions, and omissions by commercial actors that affect health."
- CDoH contribution: estimated 19 million+ deaths annually from NCDs globally.
- India's NCD burden: approximately 63% of all deaths.
- India's ICMR-NIN estimate: 56.4% of India's disease burden linked to unhealthy diets.
- Ultra-processed food sector CAGR in India: 13.37% between 2011 and 2021.
- WHO FCTC (2003): first international treaty targeting a commercial determinant (tobacco); ratified by 182 countries including India.
- India under Patents Act Section 3(d): prevents pharmaceutical evergreening — one of the strongest such protections globally.
- NPPA price-controls 348 essential medicines under NLEM.
- Jan Aushadhi (PMBJP): 10,000+ stores providing generics at 50–90% below branded prices.
- Proposed 40% GST on HFSS foods: could prevent 18.98 million DALYs and US$18 billion in health costs over 30 years (modelling study).
- India's pharmaceutical production: 20% of global generic medicine supply by volume.